Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.53 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.53 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.48 |
| ▸ | GABRP | O00591 | 2/20 | 0.46 |
| ▸ | GABRD | O14764 | 2/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.46 |
| ▸ | GABRE | P78334 | 2/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.46 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.46 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28399416 | 0.92 | ACE (0.48) | EGLN1LMNAALKBH5SUCNR1SLC15A2 | |
| SCHEMBL620412 | 0.87 | CA1 (0.36) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL11517217 | 0.83 | LMNA (0.58) | LMNAOR51E2SLC22A6TSHRNFKB1 | |
| SCHEMBL10299251 | 0.83 | SLC22A6 (0.58) | LMNAOR51E2SLC22A6TSHRNFKB1 | |
| Succinic Acid SCHEMBL1804825 | 0.81 | LMNA (0.60) | EGLN1LMNAALKBH5SUCNR1SLC15A2 | |
| SCHEMBL22223310 | 0.81 | TSHR (0.60) | LMNAOR51E2SLC22A6TSHRNFKB1 | |
| SCHEMBL11518579 | 0.81 | TSHR (0.60) | LMNAOR51E2SLC22A6TSHRNFKB1 | |
| SCHEMBL13176551 | 0.81 | TSHR (0.60) | LMNAOR51E2SLC22A6TSHRNFKB1 | |
| SCHEMBL11518693 | 0.81 | TSHR (0.60) | LMNAOR51E2SLC22A6TSHRNFKB1 | |
| SCHEMBL27050808 | 0.81 | TSHR (0.60) | LMNAOR51E2SLC22A6TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720057-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2025217212-A1 | MAC1 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025067111-A1 | MENIN-MLL INTERACTION INHIBITOR AND PREPARATION METHOD THEREFOR, AND APPLICATION | 苏州必扬医药科技有限公司 | 2025-04-03 | — | — | WO | disclosed |
| WO-2024249888-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-118530275-A | Phosphinophenyl monomer, preparation method and copolymer, preparation method and application thereof, and drilling fluid | 中国石油化工股份有限公司 | 2024-08-23 | — | — | CN | disclosed |
| US-12043833-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| US-11873288-B2 | Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230355775-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230313195-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
| CN-109956929-B | Heterocyclic derivative, preparation method, pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2023-09-19 | — | — | CN | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070117827-A1 | Compositions for affecting weight loss | U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2007-05-24 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| WO-2005097103-A2 | DIABETES AND METABOLIC SYNDROME THERAPY UTILIZING CATHEPSIN B INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| CN-1617666-A | Fused heterocyclic sulfonylurea compound, herbicide containing the same, and method for controlling weeds using the same | SUMITOMO CHEM TAKEDA AGRO CO (JP) | 2005-05-18 | — | — | CN | disclosed |
| US-20050032650-A1 | Fused heterocyclic sulfonylurea compound herbicide containing the same and method of controlling weed with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1466527-A1 | FUSED HETEROCYCLIC SULFONYLUREA COMPOUND, HERBICIDE CONTAINING THE SAME, AND METHOD OF CONTROLLING WEED WITH THE SAME | Sumitomo Chemical Takeda Agro Company, Limited (JP) | 2004-10-13 | — | — | EP | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117827-A1 | Compositions for affecting weight loss | MC4R, MC3R, MC5R | EGLN1 1048/4885LMNA 4467/4885ALKBH5 4469/4885 |
| US-20230355775-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE THEREOF | APOB, C1QBP, APOL1 | EGLN1 4649/4885LMNA 301/4885ALKBH5 821/4885 |
| US-11873288-B2 | Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) | FAAH, FAAH2, EPHX2 | EGLN1 244/4885LMNA 4459/4885ALKBH5 574/4885 |
| US-20050032650-A1 | Fused heterocyclic sulfonylurea compound herbicide containing the same and method of controlling weed with the same | NOTUM, WEE1, DDT | EGLN1 188/4885LMNA 3357/4885ALKBH5 267/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | EGLN1 2552/4885LMNA 3429/4885ALKBH5 2618/4885 |
| US-20230313195-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | PCSK9, PCSK7, PCSK6 | EGLN1 2712/4885LMNA 56/4885ALKBH5 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.